IP Library Granted Patent US 9,181,546
Granted Patent B2
US 9,181,546 · App. 13/196,436 · Granted Nov 10, 2015

Compositions for bacterial mediated gene silencing and methods of using same

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,181,546
App. No.
13/196,436
Granted
Nov 10, 2015
Kind
B2
Abstract

Methods are described for the delivery of one or more small interfering RNAs (siRNAs) to a eukaryotic cell using a bacterium. Methods are also described for using this bacterium to regulate gene expression in eukaryotic cells using RNA interference, and methods for treating cancer of cell proliferative disorders. The bacterium includes one or more siRNAs or one or more DNA molecules encoding one or more siRNAs. Vectors are also described for use with the bacteria of the invention for causing RNA interference in eukaryotic cells.

Claims (7)

1. An invasive bacterium comprising a prokaryotic vector comprising one or more DNA molecules encoding one or more siRNAs, at least one prokaryotic promoter, at least one Hly A gene and at least one Inv gene.

2. A prokaryotic vector comprising at least one DNA molecule encoding one or more siRNAs, at least one prokaryotic promoter, at least one H1yA gene and at least one Inv gene.

3. The invasive bacterium of claim 1 , wherein the invasive bacterium is non-pathogenic or non-virulent.

4. The invasive bacterium of claim 1 , wherein the invasive bacterium is an attenuated strain selected from Listeria, Shigella, Salmonella, E. Coli , and Bifidobacteriae.

5. The invasive bacterium of claim 4 , wherein the Salmonella is an attenuated strain of Salmonella typhimurium species.

6. The invasive bacterium of claim 5 , wherein the attenuated strain of Salmonella typhimurium is SL7207 or VNP20009.

7. The invasive bacterium of claim 4 , wherein the E. Coli is BM2710.

Assignments (5)
SECURITY INTEREST Recorded Nov 23, 2021
From: ADHERA THERAPEUTICS, INC.
To: CAVALRY FUND I LP
Reel/Frame 058312/0195 →
RELEASE OF SECURITY INTEREST Recorded Apr 14, 2014
From: GENESIS CAPITAL MANAGEMENT, LLC, AS AGENT
To: MARINA BIOTECH, INC.; CEQUENT PHARMACEUTICALS, INC.; MDRNA RESEARCH, INC.
Reel/Frame 032685/0158 →
SECURITY AGREEMENT Recorded May 13, 2013
From: MARINA BIOTECH, INC.; CEQUENT PHARMACEUTICALS, INC.; MDRNA RESEARCH, INC.
To: MONSANTO COMPANY
Reel/Frame 030401/0461 →
SECURITY AGREEMENT Recorded Feb 15, 2012
From: MARINA BIOTECH, INC; CEQUENT PHARMACEUTICALS, INC.; MDRNA RESEARCH, INC.
To: GENESIS CAPITAL MANAGEMENT, LLC, AS AGENT
Reel/Frame 027712/0200 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 19, 2011
From: LI, CHIANG; FRUEHAUF, JOHANNES; XIANG, SHUANGLIN
To: BETH ISRAEL DEACONESS MEDICAL CENTER
Reel/Frame 027406/0287 →